Home   Business   Life Science

Subscribe Now

Life Science




Cellular Highways hits the Highway1 launch button

Cellular Highways hits the Highway1 launch button

Cellular Highways hits the Highway1 launch button

World’s fastest chip-based cell sorting tool now available for installation.


Neobe Therapeutics closes $2.3m round for its cancer disruptor

Neobe Therapeutics closes $2.3m round for its cancer disruptor

Neobe Therapeutics closes $2.3m round for its cancer disruptor

Synthetic biology start-up acts on tumours without affecting healthy tissues.


Bidwells to support CEO of the Year at the Cambridge Independent Science and Technology Awards 2024

Bidwells to support CEO of the Year at the Cambridge Independent Science and Technology Awards 2024

Bidwells to support CEO of the Year at the Cambridge Independent Science and Technology Awards 2024

The property consultancy has worked with more than 60 science parks and innovation districts in five years.


DeepMirror launches early access programme for AI drug discovery

DeepMirror launches early access programme for AI drug discovery

DeepMirror launches early access programme for AI drug discovery

Cambridge company spun out of University in 2019.


Nicki Thompson joins Camena Bioscience as chair of the board

Nicki Thompson joins Camena Bioscience as chair of the board

Nicki Thompson joins Camena Bioscience as chair of the board

Former Amphista Therapeutics guiding light now chairs synthetic biology company.


BIOPATTERN liquid biopsy trial starts with ten NHS patients

BIOPATTERN liquid biopsy trial starts with ten NHS patients

BIOPATTERN liquid biopsy trial starts with ten NHS patients

PlaqueTec treatment is for coronary artery disease.


Science minister bit.bio’s new labs as engineering biology gets £2bn boost

Science minister bit.bio’s new labs as engineering biology gets £2bn boost

Science minister bit.bio’s new labs as engineering biology gets £2bn boost

Andrew Griffith MP opens Babraham extension as government ‘Vision’ unveiled.

2

Exonate boost for first topical diabetic macular oedema treatment

Exonate boost for first topical diabetic macular oedema treatment

Exonate boost for first topical diabetic macular oedema treatment

EXN407 success in phase Ib/IIa study.


T-Therapeutics out of the block with £48m after just 18 months

T-Therapeutics out of the block with £48m after just 18 months

T-Therapeutics out of the block with £48m after just 18 months

T-cell receptor therapeutics based on work of Prof Allan Bradley.


Lucida Medical’s AI software for prostate cancer diagnosis added to TeraRecon’s platform

Lucida Medical’s AI software for prostate cancer diagnosis added to TeraRecon’s platform

Lucida Medical’s AI software for prostate cancer diagnosis added to TeraRecon’s platform

It will help hospitals adopts the technology to speed up and improve diagnosis.


University of Cambridge scientists identify potential drug target for major cause of stroke and vascular dementia

University of Cambridge scientists identify potential drug target for major cause of stroke and vascular dementia

University of Cambridge scientists identify potential drug target for major cause of stroke and vascular dementia

They grew small blood vessel-like models in a lab from stem cells.

1

Genomic surveillance ‘must be applied to antimicrobial resistance’, say researchers

Genomic surveillance ‘must be applied to antimicrobial resistance’, say researchers

Genomic surveillance ‘must be applied to antimicrobial resistance’, say researchers

A group of nearly 100 experts says the technique used to track Covid-19 must be used for AMR.


ViaNautis’s £20m Series A success is breakthrough for polyNaut

ViaNautis’s £20m Series A success is breakthrough for polyNaut

ViaNautis’s £20m Series A success is breakthrough for polyNaut

Company renamed from SomaServe to coincide with development of pioneering platform.


AstraZeneca’s Q3 results show strong momentum – and it invests in once-a-day obesity pill

AstraZeneca’s Q3 results show strong momentum – and it invests in once-a-day obesity pill

AstraZeneca’s Q3 results show strong momentum – and it invests in once-a-day obesity pill

It secured total revenue of $11.49bn in the quarter.


This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More